AssetMark Inc’s Cellebrite CLBT Stock Holding History

AssetMark Inc’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$144	–	3198
2025 Q2	$144	Sell	9 -1,711	-99%	-$30.5K	﹤0.01%	2912
2025 Q1	$33.4K	Buy	+1,720	New	+$36.2K	﹤0.01%	1556

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return

AssetMark Inc's CLBT Position: Q3 2025 in Review

AssetMark Inc sold out of Cellebrite (CLBT) in Q3 2025, closing a stake of 9 shares — an estimated $144 sold.

AssetMark Inc first reported a position in CLBT in Q1 2025 and held it in 2 quarters. The position peaked at $33.4K in Q1 2025. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2025.

AssetMark Inc reported no remaining Cellebrite position as of Q3 2025 after selling out during the quarter.
AssetMark Inc sold 9 Cellebrite shares in Q3 2025, an estimated $144.
AssetMark Inc first reported a position in Cellebrite in Q1 2025 and held it in 2 quarters.
AssetMark Inc's Cellebrite position peaked at $33.4K in Q1 2025.
197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2025.

Based on AssetMark Inc's 13F filing for Q3 2025, filed 6 Nov 2025.